Investment analysts at Wedbush cut their Q1 2025 earnings per share (EPS) estimates for MoonLake Immunotherapeutics in a ...

Equities research analysts at Wedbush issued their FY2027 earnings per share estimates for AMC Entertainment in a report ...

Wedbush raised the firm’s price target on Janux Therapeutics (JANX) to $76 from $75 and keeps an Outperform rating on the shares following ...

Dan Ives, Global Head of Technology Research at Wedbush Securities, talks about how Deepseek has transformed China's role in ...

Wedbush analyst Matt Bryson lowered the firm’s price target on NetApp (NTAP) to $110 from $120 and keeps a Neutral rating on the shares. After ...

Dan Ives, Wedbush global head of technology research, joins 'Power Lunch' to discuss Apple's U.S. investment and Microsoft's ...

Wedbush Securites, a 70-year-old financial services firm based in Los Angeles, has filed with the Securities and Exchange ...

Dan Ives, Managing Director and Senior Equity Analyst at Wedbush Securities, shares his expert insights on the future of AI, ...

Detailed price information for Palantir Technologies Inc Cl A (PLTR-Q) from The Globe and Mail including charting and trades.

Wedbush LOS ANGELES, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Wedbush, a Los Angeles-based financial services firm with global reach, and a legacy of innovation and client-focused investment solutions ...

Wedbush Securities, a leading financial services and investment firm, is proud to announce the launch of fast and efficient services for easy-to-borrow, locates and hard-to-borrow securities.

Tesla (TSLA, $845.00) stock has the potential to reach $950 per share, says Wedbush analyst Daniel Ives. But he still doesn’t think you should buy it. The 11 Best Growth Stocks to Buy for 2021 ...